Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Arvinas, Inc. has received a consensus rating of "Moderate Buy" from 22 brokerages, with 10 analysts recommending a hold and 12 a buy.
• The average twelve-month price target for Arvinas is $19.76, while recent targets from various firms have ranged significantly, with Wells Fargo lowering theirs from $19.00 to $16.00.
• In the latest quarter, Arvinas reported a $22.40 million revenue, down 70.7% year-over-year, and an EPS of ($0.84), slightly beating the analyst estimate of ($0.87).

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-two brokerages that are covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $19.7632.

Several research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Leerink Partners restated a "market perform" rating and issued a $9.00 price target (down previously from $10.00) on shares of Arvinas in a research note on Monday, June 2nd. UBS Group cut their price target on Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Leerink Partnrs downgraded Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. Finally, Morgan Stanley cut their price target on Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $7.90 on Wednesday. Arvinas has a 52-week low of $5.90 and a 52-week high of $29.61. The firm has a market capitalization of $580.02 million, a P/E ratio of -7.82 and a beta of 2.38. The stock has a 50 day moving average price of $7.49 and a 200-day moving average price of $8.64.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.03. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%.The firm had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. During the same quarter in the prior year, the company earned ($0.49) EPS. The business's revenue was down 70.7% compared to the same quarter last year. On average, equities analysts forecast that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In related news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the sale, the chief financial officer owned 164,401 shares in the company, valued at $1,251,091.61. This represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.73% of the stock is owned by insiders.

Institutional Trading of Arvinas

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in Arvinas during the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd boosted its stake in Arvinas by 965.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock valued at $33,000 after purchasing an additional 4,219 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Arvinas by 491.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company's stock valued at $43,000 after purchasing an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company's stock worth $49,000 after buying an additional 3,500 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company's stock worth $53,000 after buying an additional 7,300 shares during the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.